BR112020005421A8 - Composição farmacêutica, método para solucionar baixa solubilidade aquosa de uma formulação de roflumilaste e método para inibir fosfodiesterase 4 em um paciente - Google Patents

Composição farmacêutica, método para solucionar baixa solubilidade aquosa de uma formulação de roflumilaste e método para inibir fosfodiesterase 4 em um paciente

Info

Publication number
BR112020005421A8
BR112020005421A8 BR112020005421A BR112020005421A BR112020005421A8 BR 112020005421 A8 BR112020005421 A8 BR 112020005421A8 BR 112020005421 A BR112020005421 A BR 112020005421A BR 112020005421 A BR112020005421 A BR 112020005421A BR 112020005421 A8 BR112020005421 A8 BR 112020005421A8
Authority
BR
Brazil
Prior art keywords
roflumilast
patient
water
pharmaceutical composition
aqueous solubility
Prior art date
Application number
BR112020005421A
Other languages
English (en)
Other versions
BR112020005421A2 (pt
Inventor
W Osborne David
Original Assignee
Arcutis Inc
Arcutis Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcutis Inc, Arcutis Biotherapeutics Inc filed Critical Arcutis Inc
Publication of BR112020005421A2 publication Critical patent/BR112020005421A2/pt
Publication of BR112020005421A8 publication Critical patent/BR112020005421A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A baixa solubilidade aquosa de roflumilaste em preparações parenterais e emulsões tópicas, suspensões, géis ou soluções pode ser melhorada incluindo-se uma mescla de solventes miscíveis em água na composição farmacêutica. A mescla de solventes miscíveis em água pode incluir éter monoetílico de dietileno glicol (Nome comercial Transcutol®; abreviado DEGEE) e água. A razão de éter monoetílico de dietileno glicol para água é de 1:10 a 20:1. A composição resultante melhorou a biodisponibilidade e eficácia e pode ser usada para inibir fosfodiesterase 4 em um paciente que precisa de tal tratamento.
BR112020005421A 2017-09-22 2018-09-19 Composição farmacêutica, método para solucionar baixa solubilidade aquosa de uma formulação de roflumilaste e método para inibir fosfodiesterase 4 em um paciente BR112020005421A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/712,900 2017-09-22
US15/712,900 US11534493B2 (en) 2017-09-22 2017-09-22 Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
PCT/US2018/051691 WO2019060379A1 (en) 2017-09-22 2018-09-19 PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST IN AQUEOUS MIXTURES OF PHARMACEUTICALLY ACCEPTABLE SOLVENTS MISCIBLE TO WATER

Publications (2)

Publication Number Publication Date
BR112020005421A2 BR112020005421A2 (pt) 2020-09-29
BR112020005421A8 true BR112020005421A8 (pt) 2022-12-13

Family

ID=63794682

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020005421A BR112020005421A8 (pt) 2017-09-22 2018-09-19 Composição farmacêutica, método para solucionar baixa solubilidade aquosa de uma formulação de roflumilaste e método para inibir fosfodiesterase 4 em um paciente

Country Status (12)

Country Link
US (2) US11534493B2 (pt)
EP (2) EP4316590A3 (pt)
JP (3) JP7191944B2 (pt)
KR (1) KR20200058402A (pt)
CN (1) CN111107836A (pt)
AU (1) AU2018337752B2 (pt)
BR (1) BR112020005421A8 (pt)
CA (1) CA3076002A1 (pt)
EA (1) EA202090813A1 (pt)
IL (1) IL273376B1 (pt)
MX (1) MX2020003001A (pt)
WO (1) WO2019060379A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210161870A1 (en) * 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
EP3801461A2 (en) * 2018-06-04 2021-04-14 Arcutis, Inc. Method and formulation for improving roflumilast skin penetration lag time
EP4041211A4 (en) * 2019-10-11 2023-09-06 Zenvision Pharma LLP IMPROVED TOPICAL COMPOSITION OF COLCHICINE
MX2022009399A (es) * 2020-01-31 2022-09-19 Arcutis Biotherapeutics Inc Formulacion topica de roflumilast que tiene mayor liberacion y semivida plasmatica.
WO2022169615A1 (en) * 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0592569A1 (en) * 1991-07-03 1994-04-20 Sano Corporation Composition and method for transdermal delivery of diclofenac
DK0706513T3 (da) 1993-07-02 2002-09-09 Altana Pharma Ag Fluoralkoxysubstituerede benzamider og anvendelse deraf som cyklisk-nukleotid phosphodiesteraseinhibitorer
GB9618974D0 (en) * 1996-09-11 1996-10-23 Glaxo Group Ltd Medicaments
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
JP2005529928A (ja) 2002-05-28 2005-10-06 アルタナ　ファルマ　アクチエンゲゼルシャフト 眼の病気を治療するためのロフルミラストの眼科的使用
PL1606261T3 (pl) 2003-03-10 2010-04-30 Astrazeneca Ab Nowy sposób przygotowania roflumilastu
US20060204526A1 (en) * 2003-08-13 2006-09-14 Lathrop Robert W Emulsive composition containing Dapsone
NZ546106A (en) * 2003-10-10 2008-10-31 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
DE102004046235A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
CA2584169A1 (en) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for chronic skin disease
FR2898499B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
US20080039405A1 (en) * 2006-04-25 2008-02-14 Croda, Inc. Modification of percutaneous absorption of topically active materials
CN101541321A (zh) * 2006-09-06 2009-09-23 Isw集团公司 局部用组合物
US7893097B2 (en) * 2008-02-02 2011-02-22 Dow Pharmaceutical Sciences, Inc. Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
US20110117182A1 (en) * 2009-07-30 2011-05-19 Allergan, Inc. Combination of dapsone with other anti-acne agents
RU2018135967A (ru) 2011-03-31 2018-11-14 Акорда Терапьютикс, Инк. Интраназальные фармацевтические композиции на основе бензодиазепина
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EA026697B1 (ru) * 2011-05-03 2017-05-31 Апониа Лабораториз, Инк. Трансдермальные композиции ибупрофена и способы их применения
WO2013030789A1 (en) 2011-08-30 2013-03-07 Ranbaxy Laboratories Limited Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
EP2903619B1 (en) 2012-10-05 2019-06-05 Robert I. Henkin Phosphodiesterase inhibitors for treating taste and smell disorders
CN110464724A (zh) 2013-01-28 2019-11-19 理森制药股份公司 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法
US20140275265A1 (en) * 2013-03-12 2014-09-18 Core Products International, Inc. Therapeutic cream for application to skin
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
WO2015132708A1 (en) 2014-03-07 2015-09-11 Torrent Pharmaceuticals Limited Pharmaceutical composition of roflumilast
EP3185852A1 (en) * 2014-08-27 2017-07-05 AbbVie Inc. Topical formulation
WO2017093857A1 (en) 2015-11-30 2017-06-08 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions
WO2017216738A1 (en) * 2016-06-15 2017-12-21 Torrent Pharmaceuticals Limited Topical compositions of apremilast
US9895359B1 (en) * 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast

Also Published As

Publication number Publication date
US11534493B2 (en) 2022-12-27
MX2020003001A (es) 2020-09-28
AU2018337752B2 (en) 2024-03-28
BR112020005421A2 (pt) 2020-09-29
EP3684334A1 (en) 2020-07-29
EP4316590A3 (en) 2024-05-01
JP7191944B2 (ja) 2022-12-19
JP2024028911A (ja) 2024-03-05
US20230091358A1 (en) 2023-03-23
EP3684334C0 (en) 2023-12-06
CA3076002A1 (en) 2019-03-28
AU2018337752A1 (en) 2020-04-09
JP2023027195A (ja) 2023-03-01
WO2019060379A1 (en) 2019-03-28
IL273376B1 (en) 2024-03-01
EP4316590A2 (en) 2024-02-07
EA202090813A1 (ru) 2020-08-14
US20190091333A1 (en) 2019-03-28
EP3684334B1 (en) 2023-12-06
JP2020534303A (ja) 2020-11-26
IL273376A (en) 2020-05-31
KR20200058402A (ko) 2020-05-27
CN111107836A (zh) 2020-05-05
JP7402301B2 (ja) 2023-12-20

Similar Documents

Publication Publication Date Title
BR112020005421A8 (pt) Composição farmacêutica, método para solucionar baixa solubilidade aquosa de uma formulação de roflumilaste e método para inibir fosfodiesterase 4 em um paciente
MX2018011881A (es) Sistema de administracion.
AR086115A1 (es) Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilos y los metodos para la preparacion y el uso de las mismas
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
AR036248A1 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
BR112016022607B8 (pt) Pó e método para aprimorar a aplicação tópica de minoxidil
EA201600118A1 (ru) Жидкая водная фармацевтическая композиция с консервантами, содержащая этерифицированные производные циклодекстрина
FI2887923T3 (fi) Polyoksylilipidin tai polyoksylirasvahapon oftalminen formulaatio ja silmätilojen hoito
BR112018001114A2 (pt) ingrediente cosmético, formulação cosmética, utilização da mesma, processo de precipitação seletiva de pongamol em um óleo de caranja
EA201400942A1 (ru) Топические композиции, содержащие фипронил и перметрин, и способы их применения
CO2019002555A2 (es) Composición farmacéutica
EA200600528A1 (ru) Способ получения водорастворимых дитерпенов и их применение
BR112016025126A8 (pt) Formulação líquida compreendendo composto neutralizante de gm-csf
BR112015021124A2 (pt) solução para acne
BR112018070448A2 (pt) derivados de aminotiazol úteis como agentes antivirais
WO2018079568A3 (ja) ゲル状組成物
MX2020003883A (es) Composiciones que contienen derivados de acido benzoico o acido furoico y uso de los derivados para estabilidad de emulsion y de espuma.
BR112023022484A2 (pt) Composto na fórmula geral (i) ou um sal farmaceuticamente aceitável deste, composição farmacêutica e uso do composto ou sais farmaceuticamente aceitáveis deste
BR112015019580A2 (pt) processo para preparar uma solução aquosa, solução aquosa, medicamento, alimento, ingrediente de alimento ou suplemento alimentício e método para reduzir a assimilação calórica
BR112018070626A2 (pt) formulação farmacêutica, e, composto ou composição para uso, uso, método ou composição
ES2880437T3 (es) Nuevas composiciones tópicas que comprenden ácido úsnico y su uso terapéutico
MX2021014614A (es) Composiciones terapeuticas estables en solventes polares aproticos y metodos de elaboracion de las mismas.
JP2013213023A5 (pt)
WO2020047360A8 (en) Benzimidazole compounds and use thereof for treating alzheimer's disease or huntington's disease
FR3031301B1 (fr) Nouvelle composition associant derives de chromone et de tyrosine pour le traitement de la peau

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ARCUTIS BIOTHERAPEUTICS, INC. (US)

B25G Requested change of headquarter approved

Owner name: ARCUTIS BIOTHERAPEUTICS, INC. (US)